Navigation Links
Puma Biotechnology Announces Completion of Private Placement
Date:11/23/2011

LOS ANGELES, Nov. 23, 2011 /PRNewswire/ -- Puma Biotechnology, Inc., a development stage biopharmaceutical company, today announced that on November 18, 2011, the Company completed the second tranche of its $60 million private financing. In the first tranche, announced on October 5, 2011, Puma sold approximately 14.7 million shares of its common stock to institutional investors at a purchase price of $3.75 per share, resulting in gross proceeds of $55 million.  In this second tranche, the Company sold approximately 1.3 million shares of its common stock to accredited investors at the same purchase price of $3.75 per share for gross proceeds of $5 million.  Proceeds from the financing will be used primarily to fund the continued clinical development of PB-272 (oral neratinib).

Leerink Swann LLC acted as lead placement agent and National Securities Corporation acted as co-placement agent for the second tranche of Puma's private financing. 

The securities sold in Puma's private financing have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Puma Biotechnology

Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer.  The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing
'/>"/>

SOURCE Puma Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
2. Yongye Biotechnology International Retains CCG Investor Relations
3. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
4. Yongye Biotechnology International Announces Second Quarter Results
5. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
6. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
7. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
8. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
10. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
11. InNexus Biotechnology Strengthens Patent Team With New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... , March 25, 2015  S&P Capital IQ ... Factual Stock Report coverage on Abattis Bioceuticals Corp ... CSE: ATT): is a specialty biotechnology company with ... licensing and marketing proprietary ingredients, bio-similar compounds, patented ... North America . The company ...
(Date:3/25/2015)... Accelovance, a therapeutically focused contract research organization ... Research Organization" at the upcoming Vaccine Industry Excellence (ViE) ... This is the eighth consecutive year Accelovance has ... for "Best Contract Research Organization" in 2009, 2010, and ... "We,re excited to be a finalist for ...
(Date:3/25/2015)... An increase of awareness related to ... of food nutrients, regulatory changes and concerns related to ... demand for natural astaxanthin over the past few years. ... their capacities to satisfy the rising demand. , ... astaxanthin (used in nutraceuticals, aqua feed, food and beverages ...
(Date:3/25/2015)... 25, 2015 Data from Evidence ... of Action in Neuromuscular Diseases , South ... Incorporated (Nasdaq: CYTK) announced the publication of a ... activator tirasemtiv in the journal Neurotherapeutics. This ... of Effect” or hypothesis-generating clinical trial which evaluated ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... , Gains US Patent Protection for ... (Euronext: AMT), a leader in the field of human ... an exclusive license agreement with the US National Institutes ... 5 (AAV5)-based gene therapy vectors for liver and brain ...
... 2, 2011 This September, during Prostate Cancer Awareness ... cancer screening method that may change the face of ... Cleveland hospitals and one Boston hospital, analyzed by the National ... urine screening. Dr. David Samadi, Vice Chairman, Department of ...
... mysterious inner workings of the malaria parasite has revealed ... thanks in part to a single, crucial chemical that ... the University of California, San Francisco (UCSF) and Stanford ... Biology , this insight immediately provides a powerful new ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health 2Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health 3More Precise Prostate Cancer Screening on Horizon 2More Precise Prostate Cancer Screening on Horizon 3Malaria discovery gives hope for new drugs and vaccines 2Malaria discovery gives hope for new drugs and vaccines 3Malaria discovery gives hope for new drugs and vaccines 4Malaria discovery gives hope for new drugs and vaccines 5
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... March 10, 2015  Continuing its 167-year history of ... Schlemmer introduces The Eye Scanning Password Authenticator , ... access to secure websites or sensitive data. ... at international borders, the device has a small camera ... of the iris, converting them into an encrypted ID ...
(Date:3/10/2015)... Utah , March 10, 2015   Tute ... interpretation, has been selected by next-generation sequencing company ... of whole exome and targeted gene panel interpretation. ... provider, has adopted the most current technologies to support ... genetic research. The company offers two types of exome ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3
... Dec. 12, 2011  The Evermedia Group, Inc. (Pinksheets: ... Markets last month, raising the Company,s listing from ... Current Information tier, the highest level of reporting ... Evermedia submitted an Initial Company Information and Disclosure ...
... Cancer Center at University Hospitals (UH) Case Medical Center and ... findings in 25 presentations this weekend at the 53rd Annual ... San Diego Convention Center. "The breadth ... is truly outstanding," says Stan Gerson, MD, Director of the ...
... 15, 2011 The Los Angeles World Airports (LAWA), which ... awarded a contract modification to Unisys (NYSE: UIS ... used to identify the 45,000 airport employees, contractors, police and ... The work is an early step in LAWA,s plan to ...
Cached Biology News:The Evermedia Group, Inc. Advances Corporate Transparency Efforts 2The Evermedia Group, Inc. Advances Corporate Transparency Efforts 3UH Seidman Cancer Center researchers present at American Society of Hematology Annual Meeting 2UH Seidman Cancer Center researchers present at American Society of Hematology Annual Meeting 3Los Angeles World Airports Selects Unisys to Upgrade ID Card Reader System and Network 2Los Angeles World Airports Selects Unisys to Upgrade ID Card Reader System and Network 3
...
Request Info...
... Transformation Kit is designed for rapid ... Advantages over commonly used transformation procedures ... methods include:- Cells can be made competent ... cell preparation and transformation solutions are ...
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
Biology Products: